MLAB - Mesa Laboratories, Inc.
LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 2026 at approximately 6:00 A.M. Eastern Time (ET) on Wednesday, May 27, 2026.
LAKEWOOD, Colo. , April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0. 16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.
Mesa Laboratories, Inc. (NASDAQ: MLAB - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $79.16 and traded as high as $82.50. Mesa Laboratories shares last traded at $81.13, with a volume of 99,075 shares traded. Analyst
Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.
Principal Financial Group Inc. lessened its stake in Mesa Laboratories, Inc. (NASDAQ: MLAB) by 66.2% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,065 shares of the medical instruments supplier's stock after selling 19,713 shares during the quarter. Principal Financial Group
Diamond Hill Capital Management Inc. grew its holdings in shares of Mesa Laboratories, Inc. (NASDAQ: MLAB) by 218.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,381 shares of the medical instruments supplier's stock after purchasing an additional 84,582
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Tuesday, February 3rd. Analysts expect the company to announce earnings of $2.41 per share and revenue of $63.2330 million for the quarter. Individuals may visit the the company's upcoming Q3 2026 earning results page for
Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript